Oral solution NRT
This article was originally published in The Tan Sheet
Executive Summary
FDA denies Nico Worldwide's petition to file ANDAs for its nicotine oral solution, citing a need for human clinical trials to determine safety and efficacy. The Pacific Palisades, Calif.-based firm compared its generic nicotine polacrilex 2 mg and 4 mg base per 240 mL oral solutions to GlaxoSmithKline's Commit nicotine lozenges in the ANDA suitability petitions (1"The Tan Sheet" Aug. 2, 2004, In Brief). The oral solution is "unlikely to be bioequivalent to the approved lozenge" due to the different sites of absorption for the GSK and Nico Worldwide products, FDA states...
You may also be interested in...
FDA Criminal Probe Of Nic Lite Seller Should Be Considered – Public Citizen
Public Citizen is asking FDA to consider whether criminal prosecution of Nico Worldwide is an appropriate response to the firm's continued marketing of its nicotine water product Nic Lite as a dietary supplement
Oral solution NRT?
Nicoworldwide is pursuing FDA approval of generic nicotine polacrilex, bitartrate and base solutions equivalent to GlaxoSmithKline's Commit nicotine lozenge. In three separate ANDA suitability petitions submitted to FDA in early July, the Pacific Palisades, Calif.-based firm requests permission to file ANDAs for the three nicotine drugs, all in a 2 mg and 4 mg base per 240 mL oral solution. Although the proposed products would feature a different dosage form than the GSK lozenge, they would "not differ from the listed drug in strength (base form) or route of delivery," Nicoworldwide says...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.